Immunocore Advances Half-Life Extended Cancer Treatment With First Patient Dosed
Immunocore Advances Half-Life Extended Cancer Treatment With First Patient Dosed
Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C (PRAME-HLE-A02), which is a half-life extended ImmTAC candidate.
Immunocore Holdings plc（納斯達克：IMCR）（"Immunocore"或"公司"）是一家商業階段的生物技術公司，開創並提供變革性的免疫調節藥物，以顯著改善癌症、傳染病和自身免疫疾病患者的治療效果。今天宣佈，第一位患者已在IMC-P115C（PRAME-HLE-A02）一期臨牀試驗中接受了用藥，該藥物爲半衰期延長的ImmTAC候選藥物。
IMC-P115C was developed to improve patient convenience by reducing the frequency of treatment administration. It is Immunocore's first half-life extended candidate, and sixth ImmTAC candidate to enter the clinic. IMC-P115C is a PRAME x CD3 ImmTAC bispecific protein, with the same CD3 and targeting the same HLA-A*02:01 PRAME (PReferentially expressed Antigen in MElanoma) peptide as brenetafusp.
IMC-P115C的開發旨在通過減少治療給藥的頻率來提高患者的便利性。它是Immunocore的第一個半衰期延長的候選藥物，也是第六個進入臨牀的ImmTAC候選藥物。IMC-P115C是一種PRAME x CD3的ImmTAC雙特異性蛋白，具有相同的CD3並針對與brenetafusp相同的HLA-A*02:01 PRAME（優先表達的黑色素瘤抗原）肽。
譯文內容由第三人軟體翻譯。
